Holen Sie sich die Stockscreener-App
20.45
0.60%
0.11
Schlusskurs vom Vortag:
$20.34
Offen:
$20.34
24-Stunden-Volumen:
121.48K
Relative Volume:
0.09
Marktkapitalisierung:
$2.50B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
17.33
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
+1.95%
1M Leistung:
-2.61%
6M Leistung:
-5.36%
1J Leistung:
-0.04%
1-Tages-Spanne:
$20.29
$20.51
1-Wochen-Bereich:
$19.91
$20.80
52-Wochen-Spanne:
$19.00
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.46 | 2.48B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.13 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.49 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.94 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
666.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
310.14 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Risk adjusted return profile for Catalyst Pharmaceuticals Inc. analyzed2025 Institutional Moves & Consistent Profit Trade Alerts - Newser
How moving averages guide Catalyst Pharmaceuticals Inc. tradingJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
Vanguard Group Inc. Buys 64,486 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - Defense World
Published on: 2025-08-20 03:26:00 - Newser
Is Catalyst Pharmaceuticals Inc. stock entering bullish territory2025 Sector Review & Growth Oriented Trade Recommendations - Newser
Catalyst Pharmaceuticals Inc. stock prediction for this weekLayoff News & Community Consensus Stock Picks - Newser
How to recover losses in Catalyst Pharmaceuticals Inc. stockGold Moves & Real-Time Chart Breakout Alerts - Newser
Published on: 2025-08-19 23:16:32 - Newser
Is it time to cut losses on Catalyst Pharmaceuticals Inc.Quarterly Portfolio Review & Entry Point Confirmation Signals - Newser
How to escape a deep drawdown in Catalyst Pharmaceuticals Inc.Rate Hike & Daily Growth Stock Investment Tips - Newser
Volume spikes in Catalyst Pharmaceuticals Inc. stock – what they mean2025 Retail Activity & High Accuracy Trade Signal Alerts - Newser
Strategies to average down on Catalyst Pharmaceuticals Inc.July 2025 Breakouts & Reliable Trade Execution Plans - Newser
What data driven models say about Catalyst Pharmaceuticals Inc.’s futureMarket Growth Summary & Stock Portfolio Risk Control - Newser
Published on: 2025-08-19 06:55:29 - Newser
How to track smart money flows in Catalyst Pharmaceuticals Inc.2025 Market Sentiment & Short-Term High Return Ideas - Newser
Sector Leaders Rotate Capital Into Catalyst Pharmaceuticals Inc.2025 Big Picture & Free Community Supported Trade Ideas - kangso.co.kr
What technical models suggest about Catalyst Pharmaceuticals Inc.’s comeback2025 Top Gainers & Long-Term Growth Stock Strategies - Newser
Identifying reversal signals in Catalyst Pharmaceuticals Inc.2025 Buyback Activity & Daily Profit Maximizing Trade Tips - Newser
What high frequency data says about Catalyst Pharmaceuticals Inc.2025 Institutional Moves & Weekly Watchlist for Consistent Profits - Newser
Published on: 2025-08-17 22:31:22 - Newser
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyJuly 2025 Snapshot & Fast Moving Stock Watchlists - Newser
Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $33.20 - Defense World
Is Catalyst Pharmaceuticals Inc. still worth holding after the dip2025 Top Decliners & Daily Profit Focused Screening - Newser
Catalyst Pharmaceuticals Inc.’s volatility index tracking explained2025 Buyback Activity & Free Long-Term Investment Growth Plans - Newser
What is the next catalyst for EyePoint Pharmaceuticals Inc.Rate Hike & Technical Pattern Recognition Alerts - thegnnews.com
Does Catalyst Pharmaceuticals Inc. show high probability of rebound - Newser
Catalyst Pharmaceuticals Inc. stock trendline breakdownMarket Trend Review & Community Shared Stock Ideas - Newser
US Bancorp DE Has $178,000 Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Smart tools for monitoring Catalyst Pharmaceuticals Inc.’s price actionMarket Performance Summary & Fast Moving Stock Watchlists - Newser
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Catalyst Pharmaceuticals (NASDAQ:CPRX) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance
Catalyst Pharmaceuticals: A Cheap but Developing Biopharma Name - AInvest
Catalyst Pharmaceuticals: A Developing Story That's Cheap Enough (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals shares rise 2.54% intraday after Xenon Pharmaceuticals reports positive Phase 3 study progress and commercial leadership appointment. - AInvest
Why Catalyst Pharmaceuticals Inc. stock is on top investor watchlistsFree Consistent Profit Pattern Recognition Tools - Newser
Catalyst Pharmaceuticals shares rise 1.26% premarket due to growth in Sterilization Medical Packaging Market. - AInvest
XTX Topco Ltd Sells 15,179 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Cetera Investment Advisers Has $1.41 Million Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion - MSN
Catalyst Pharma Receives Buy Rating and Price Target of $34.00 from Bank of America Securities Analyst Jason Gerberry. - AInvest
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to “Hold” at Wall Street Zen - Defense World
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Catalyst Pharma Reports Record Q2 2025 Financial Results - The Globe and Mail
Catalyst Pharma Updates Guidelines for SCLC Treatment - TipRanks
Transcript : Catalyst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Catalyst Pharmaceuticals Q2 2025 beats EPS forecast By Investing.com - Investing.com South Africa
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Catalyst Pharmaceuticals Inc-Aktie (CPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sundaram Preethi | Chief Strategy Officer |
Jun 11 '25 |
Sale |
26.42 |
1,600 |
42,272 |
41,081 |
1.03%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):